

## CASE STUDY

# AES Helped to Put a Sponsor at the Forefront of a Chronic Disease Market

### AT A GLANCE

Indication: **Type 2 Diabetes**



Enrollment time saved:

**256**  
days


### THE CHALLENGE

This sponsor was in a crucial race in the diabetes space as it began Phase III clinical trials for a new class of drug for type 2 diabetes. They were rolling into a crowded field of companies developing competitive compounds.

The competition was stiff, but the race was worth winning. If their drug was approved, it could capture a major share of a market that was projected to nearly double to \$50 billion by 2022.

### THE PLAN


Knowing that a compound that gets to market first generally maintains the lead throughout the product's lifecycle, the clinical trial team hired Accelerated Enrollment Solutions (AES) to provide enrollment support for 8 protocols.



## THE RESULTS

### AES played a key role in winning the race to market.

- Across all protocols supported, AES increased the average randomizations per site by as much as 149%.
- In the final 2 years of the trial, AES delivered 75% of US randomizations and 29% of all randomizations.



## THE BENEFITS

By increasing site enrollment rates, AES helped the sponsor reach its randomization commitments by as much as 256 days (~8.5 months) faster than waiting for sites to find enough patients unassisted.

### About AES

**Accelerated Enrollment Solutions (AES)** is the new standard in clinical trial productivity. Our innovative and integrated site and patient services secure the success of clinical trials by providing enrollment, timing, and budget certainty.

14600819

### Corporate Headquarters

2 Walnut Grove Drive  
Horsham, PA 19044  
1.215.323.9000 (press 2 to learn more)  
globalAES.com

Email: [enrollment.certainty@globalAES.com](mailto:enrollment.certainty@globalAES.com)